Available today, the proteoCHIP 12*16 facilitates automated, miniaturized solutions for single cell proteomics applications
Today, SCIENION & Cellenion, BICO companies, announced the release of the proteoCHIP 12*16, the first available solution enabling reproducible automated miniaturized single cell proteomics sample preparation and standardized workflow for multiplexed single cell mass spectrometry-based proteomics analysis. The proteoCHIP 12*16 was developed in partnership with the Research Institute of Molecular Pathology (IMP) in Vienna, Austria.
The proteoCHIP further extends the capabilities of cellenONE®, Cellenion’s unique platform for single cell isolation and ultra-small volume dispensing, by facilitating miniaturized sample preparation of individual cells for single cell proteomics workflows.
“We are delighted to launch the proteoCHIP consumable range developed in collaboration with Karl Metchler’s group at IMP Biocenter in Vienna,” said Guilhem Tourniaire, PhD, Managing Director & Founder at Cellenion. “We know that many of our existing and prospective customers have been waiting for its release since the publication of the first data last April. This dedicated consumable is going to both facilitate and improve sample preparation for single cell proteomic studies and will be a cornerstone toward the democratization of this new revolutionary field of Biology.”
A market leading instrument in single cell isolation and dispensing, cellenONE® enables users to dispense and prepare a single cell in each well of the proteoCHIP, including cell lysis, protein digestion, peptide labelling and quenching. While conventional workflows lack automation and involve a lot of user intervention and manual sample handling steps, the combination of cellenONE® and proteoCHIP enable all the front-end of the Mass Spectrometry on a single instrument with minimal user intervention, allowing preparation of up to 576 single cells per run. The proteoCHIP, together with its Funnel and Accessory Kit, also enables easy sample pooling by centrifugation then direct injection into the LC/MS-MS autosampler, leading to maximum liquid recovery and minimal peptide loss.
“We are looking forward to having everyone apply our proteoCHIP to their samples for highly sensitive and reproducible single-cell proteomics data,” said Karl Mechtler, Head of Protein Chemistry Facility at the Research Institute of Molecular Pathology (IMP). “The automatization of the temperature and humidity-controlled workflow at low nanoliter volumes within the cellenONE® will allow a multitude of labs to further drive the technology with many exciting applications”.
Companies interested in purchasing the proteoCHIP 12*16 can visit: https://www.cellenion.com/products/proteochip/
BICO Press office
Riley Munks, PR Manager (650) 863-6699
Alyssa D’Orazio, PR Manager (617) 634-9601
Email: [email protected]
Founded in 2001, SCIENION is a renowned specialist in ultra-low volume precision liquid handling in the pico-liter to micro-liter range, enabling applications from research to high-throughput production of assays in diagnostics and life sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION is a complete solution provider offering a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing services. The company operates from two sites in Germany, Dortmund and Berlin, and has subsidiaries in Arizona, USA; Chichester, UK; and Cellenion in Lyon, France.
SCIENION is part of BICO, the leading bio convergence company in the world that provides technologies, products and services to create the future of health.
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on the Nasdaq the Stockholm under BICO. www.bico.com